Co-founder and CEO
Dr.Kuninobu has 15 years+ experience in the pharmaceutical industry. He led the US regulatory and clinical affairs of the department of regenerative medicines in NIPRO until 2022 in collaboration with Yale University
Co-founder and CSO
Professor of Kyushu University. Dr.Yamada is the Principal investigator of basic research on elucidation of disease mechanisms and drug discovery by targeting oxidized lipids. He worked as a research fellow in NIH(NIH/NCI: Dr. Murali C. Krishna)
Consultant Medical Director
Dr.Tari has 16 years+ experience as a pharmaceutical executive in ophthalmology. He served as Senior Director of Medical Affairs at Regeneron, Global Medical Lead, and Senior Medical Director at Astellas.
Aiko Kato Sullenberger
Boston Operations Manager
Aiko has ten years of experience in research and business development in Daikin Global HQ. She handles its CVC operation in Boston up to 2020. In Allm USA, she engaged in scouting opportunities to digital health solutions to US medical institutions. Experience at CIC expanded her network of life science and VCs in greater Boston area.
Robert M. Ward, M.D.
Dr.Ward was the former chair of the American Academy of Pediatrics Committee on Drugs began the Pediatric Pharmacology Program at the University of Utah School of Medicine and served as an attending neonatologist and medical director of the Primary Children’s Hospital NICU. He has published widely and lectured internationally.
Darius M. Moshfeghi, M.D.
Chief of Retina Professor of Ophthalmology Stanford University School of Medicine
Dr.Moshfeghi is an internationally-recognized expert in pediatric vitreoretinal disease and pediatric retinal telemedicine. He has dedicated his career to using telemedicine and digital technology to prevent blindness in children.
Kenichi Shimada, Ph.D.
Laboratory of Systems Pharmacology Harvard Medical School
Dr.Shimada received his Ph.D. for the elucidation of the mechanisms of ferroptosis, a form of non-apoptotic cell death phenotype, under the supervision of Dr. Brent Stockwell at Columbia Univeristy. In 2015, he came to HMS and continued his training as a postdoctoral fellow with Dr. Timothy Mitchison and has published a few papers in mechanistic toxicology and cancer signaling.
Norman Barton, M.D., Ph.D.
Ex-Global Head Clinical Sciences Rare Metabolic Disorders and Neonatology in Takeda(Shire)
Dr.Barton is an experienced executive with substantive accomplishments in rare diseases. He has 40 years of experience in orphan drug product development in leadership positions with strategic, operational, and management responsibilities at Takeda and Shire, including the retinopathy of prematurity (ROP) program.
Robert Bhisitkul, M.D., Ph.D.
Professor of Retina of UCSF.
Dr.Bhisitkul is an ophthalmologist and retina specialist who provides medical and laser treatment for macular degeneration, diabetic retinopathy and other retinal diseases. He also performs surgery on macular hole and macular pucker, retinal detachment and complications of diabetic eye disease.
Christian Ofslager has spent 35 years in sterile drug development and manufacturing and has developed several commercial products and has wide experience in developing liquid & lyophilized vial, frozen bag and prefilled syringe drug products. During that time he spent 24 years in Wyeth formulations development and 10 years at Pfizer in development and manufacturing.